Table 3.
ICURs – base-case scenario and ten-year time horizon scenario / 1,000 individuals
| Costs ($) | Incremental costs ($) | QALYs | Incremental QALYs | ICUR ($/QALY) | |
|---|---|---|---|---|---|
|
MoH perspective
| |||||
| Base-case scenario | |||||
| Olanzapine |
9,729,158 |
-3,847,300 |
3,301 |
84.84 |
dominant |
| Asenapine (Saphris®) |
5,881,858 |
|
3,386 |
|
|
| Ten-year time horizon scenario | |||||
| Olanzapine |
18,233,001 |
-6,956,705 |
5,784 |
160.67 |
dominant |
| Asenapine (Saphris®) |
11,276,296 |
|
5,945 |
|
|
|
Societal perspective
| |||||
| Base-case scenario | |||||
| Olanzapine |
11,466,846 |
-3,878,343 |
3,301 |
84.84 |
dominant |
| Asenapine (Saphris®) |
7,588,702 |
|
3,386 |
|
|
| Ten-year time horizon scenario | |||||
| Olanzapine |
22,527,000 |
-7,131,099 |
5,784 |
160.67 |
dominant |
| Asenapine (Saphris®) | 15,395,901 | 5,945 | |||